8-K: Calidi Biotherapeutics Adjusts Executive Compensation and Sets Bonus Targets

Calidi Biotherapeutics has increased the base salary and bonus target for executive Wendy Pizarro, and set a bonus contingent on a successful capital raise.

Summary

• Calidi Biotherapeutics' Compensation Committee approved adjustments to the compensation of executive Wendy Pizarro, effective May 13, 2024.
• Ms. Pizarro's annualized base salary was increased by $25,000 to $425,000.
• Her annual discretionary bonus target was increased from 30% to 40% of her base salary.
• Ms. Pizarro is also eligible for a $120,000 bonus if the company closes a $10 million debt or equity round by December 31, 2024.
• The final bonus amount will be determined by the Chief Executive Officer based on Ms. Pizarro's involvement and support.

Sentiment

Score: 7

Explanation: The document indicates positive steps in incentivizing a key executive, but also highlights the need for a successful capital raise, which introduces some uncertainty.

Positives

• The increase in base salary and bonus target for Ms. Pizarro may incentivize her performance.
• The potential $120,000 bonus tied to a capital raise could motivate her to support the company's fundraising efforts.

Risks

• The $120,000 bonus is contingent on the company successfully raising $10 million by the end of the year, which may not be guaranteed.
• The increased compensation for Ms. Pizarro will increase the company's operating expenses.

Future Outlook

The company is aiming to raise $10 million in debt or equity financing by December 31, 2024, which is tied to an executive bonus.

Management Comments

• The Compensation Committee of the Board of Directors approved the compensation adjustments for Wendy Pizarro.
• The Chief Executive Officer will determine the final bonus amount for Ms. Pizarro based on her involvement and support in the capital raise.

Industry Context

Executive compensation adjustments are common in the biotech industry to retain and incentivize key personnel, especially those involved in fundraising efforts.

Comparison to Industry Standards

• Executive compensation in the biotech industry varies widely based on company size, stage of development, and financial performance.
• A base salary of $425,000 for an executive is within the typical range for a company of Calidi's size and stage, but the bonus structure is more specific to the company's immediate needs.
• Comparable companies in the biotech sector often use a combination of base salary, stock options, and performance-based bonuses to attract and retain talent.

Stakeholder Impact

• Shareholders may view the increased compensation as a positive sign of the company's commitment to retaining key talent.
• Employees may see the potential bonus as a positive sign of the company's growth prospects.
• Creditors and investors will be interested in the company's ability to secure the $10 million capital raise.

Next Steps

• The company will need to focus on securing the $10 million debt or equity financing by December 31, 2024.
• The Chief Executive Officer will determine the final bonus amount for Ms. Pizarro based on her involvement and support in the capital raise.

Key Dates

Keywords

executive compensation, bonus, salary, capital raise, debt financing, equity financing, Calidi Biotherapeutics